Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies (NCT03739931) | ModernaTX, Inc. | 2018-11-27 |
Track Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.